Description
Latin name
REAFERON-LIPINT
Release form
Hard gelatine capsules, white content of the capsules is a fine crystalline hygroscopic powder of white or white with a yellowish tint.
Pharmacological action
The drug has an immunomodulating and antiviral effect. Interferon alpha-2b human recombinant, which is the active substance in the preparation, It is synthesized by bacterial cells of the strain Escherichia coli SG-20050 / plF16, in the genetic apparatus of which the human interferon alpha-2b gene is integrated. It is a protein containing 165 amino acids, and is identical in characteristics and properties to human leukocyte interferon alpha-2b.
The antiviral effect of interferon alpha-2b is manifested during the reproduction of the virus by active inclusion in the metabolic processes of cells. Interferon, interacting with specific receptors on the cell surface, initiates a number of intracellular changes, including the synthesis of specific cytokines and enzymes (2-5-adenylate synthetases and protein kinases), whose action inhibits the formation of viral protein and viral ribonucleic acid in the cell.
The immunomodulatory effect of interferon alpha-2b is manifested in an increase in the phagocytic activity of macrophages, an increase in the specific cytotoxic effect of lymphocytes on target cells, a change in the quantitative and qualitative composition of secreted cytokines, a change in the functional activity of immunocompetent cells, a change in the production and secretion of intracellular proteins.
Indications
– treatment of influenza and other acute respiratory viral diseases in adults as part of the complex therapy
– prevention of influenza and other acute respiratory viral diseases in adults during the epidemic and season.
Contraindications
– children under 18 years of age
– pregnancy
– lactation period
– lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome
– hypersensitivity to the drug interferon or any other component.
Precautions
– renal and / or liver failure
– severe myelosuppression.
Special instructions
Seek medical attention if you experience any allergic reactions.
Effect on the ability to drive vehicles, mechanisms
The use of the drug does not affect the ability to drive a vehicle or potentially dangerous mechanisms.
Composition
1 caps. – interferon alpha-2b human recombinant 500,000 IU.
Excipients: sodium chloride – 8.01 mg, sodium phosphate, disubstituted, 12-water (sodium hydrogen phosphate dodecahydrate) – 4.52 mg, sodium dihydrogen phosphate monosodium phosphate dihydrogen – 2-aqueous – 0.56 mg, lactose monohydrate – 91.3 silicon dioxide 4-. 3. – 7.54 mg (not more than 5%).
Composition of capsule shell (body and lid): titanium dioxide (E171) – 2%, gelatin – up to 100%.
Dosage and administration
The drug is taken orally, 30 minutes before a meal.
In the treatment of influenza and SARS – 500 000 IU (1 capsule) daily 2 times / day for 5 days.
For the prevention of influenza and SARS – 500,000 ME (1 capsule) per day, 2 times a week for a month.
If swallowing is difficult, the capsules are carefully opened and the contents taken with a small amount of water.
Side effects
Allergic reactions, flu-like syndrome (chills, fever, feeling tired, lethargy, headache, myalgia, arthralgia, decreased appetite) are possible.
Drug interaction
Interferon alfa is able to reduce the activity of cytochrome P450 and, therefore, affect the metabolism of cimetidine, fepitoip, chimetry, theophylline, diazepam, propranolol, warfarin. some cytostatics. May enhance neurotoxic. myelotoxic or cardiotoxic effects of drugs prescribed earlier or simultaneously with it. Co-administration with drugs that depress the central nervous system, immunosuppressive drugs (including oral and parenteral forms of corticosteroids) should be avoided. Drinking alcohol during treatment is not recommended.
Overdose
No drug overdose was observed. Dose-dependent side effects may increase. Treatment is symptomatic.
Storage Conditions
The product should be stored in a dark place and out of reach of children at a temperature not exceeding 8 ° C. Expiration – 2 years.
Not applicable after the expiry date stated on the package.
Shelf life
2 years.
Not to be used after the expiration date printed on the package.
Deystvuyushtee substance
interferon alyfa-2b
Terms and conditions
prescription
